Want to see NKTX full AI Analyst Report?
Top Page
Nkarta
(NASDAQ:NKTX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▼(-42.97% Downside)
Action:Reiterated
Date:10/28/26
The score is driven primarily by weak financial performance (pre-revenue, sizable losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD and very weak RSI/Stoch). Valuation provides limited support due to a negative P/E and no dividend yield data.
Positive Factors
Off-the-shelf NK therapy platform
An allogeneic, off-the-shelf approach could support more standardized product development and broader treatment access than individualized cell therapies. Nkarta’s engineering and manufacturing focus provides a coherent platform for advancing multiple oncology candidates over time.
Negative Factors
No revenue base
With no reported revenue, Nkarta has not yet demonstrated commercial demand or an operating model that can fund its activities internally. Future financial performance therefore remains dependent on clinical progress and eventual product commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Off-the-shelf NK therapy platform
An allogeneic, off-the-shelf approach could support more standardized product development and broader treatment access than individualized cell therapies. Nkarta’s engineering and manufacturing focus provides a coherent platform for advancing multiple oncology candidates over time.
Read all positive factors
Nkarta (NKTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$121.76M
Dividend YieldN/A
Average Volume (3M)791.16K
Price to Earnings (P/E)―
Beta (1Y)1.93
Revenue GrowthN/A
EPS Growth-6.70%
CountryUS
Employees106
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.57
Shares Outstanding71,624,794
10 Day Avg. Volume1,163,680
30 Day Avg. Volume791,163
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.83
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-43.42
Enterprise Value/Ebitda-0.94
Forecast
1Y Price Target
$11.75Price Target Upside346.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.67
Revenue Forecast (FY)N/A
Nkarta Business Overview & Revenue Model
Company Description
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR ...
Nkarta Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -2.34M | -9.19M | 0.00 | -5.87M | 0.00 | 0.00 |
| EBITDA | -107.69M | -94.89M | -99.64M | -120.48M | -105.61M | -84.32M |
| Net Income | -117.32M | -104.08M | -108.79M | -117.50M | -113.84M | -86.08M |
Balance Sheet | ||||||
| Total Assets | 337.64M | 404.21M | 501.20M | 378.88M | 472.94M | 273.90M |
| Cash, Cash Equivalents and Short-Term Investments | 182.76M | 276.28M | 267.35M | 248.19M | 352.14M | 238.09M |
| Total Debt | 73.54M | 76.42M | 80.27M | 88.34M | 82.93M | 12.46M |
| Total Liabilities | 89.91M | 91.88M | 93.23M | 105.60M | 100.73M | 22.94M |
| Stockholders Equity | 247.74M | 312.32M | 407.98M | 273.29M | 372.21M | 250.97M |
Cash Flow | ||||||
| Free Cash Flow | -93.90M | -89.91M | -104.11M | -114.31M | -104.11M | -72.95M |
| Operating Cash Flow | -92.76M | -88.70M | -99.70M | -86.16M | -57.00M | -67.93M |
| Investing Cash Flow | 63.55M | 100.32M | -129.56M | 79.02M | -184.69M | 32.53M |
| Financing Cash Flow | 746.00K | 141.00K | 226.08M | 691.00K | 219.01M | 1.20M |
Nkarta Technical Analysis
Negative
2.63
Price Trends
2.49
Negative
2.55
Negative
2.54
Negative
Market Momentum
-0.24
Positive
24.30
Positive
29.09
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NKTX, the sentiment is Negative. The current price of 2.63 is above the 20-day moving average (MA) of 2.08, above the 50-day MA of 2.49, and above the 200-day MA of 2.54, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 24.30 is Positive, neither overbought nor oversold. The STOCH value of 29.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NKTX.
Nkarta Risk Analysis
Nkarta disclosed 80 risk factors in its most recent earnings report. Nkarta reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nkarta Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | $186.61M | 5.25 | 42.57% | ― | 234.18% | ― | |
56 Neutral | $579.10M | -11.31 | -43.57% | ― | -66.63% | 57.89% | |
56 Neutral | $601.96M | -14.08 | -169.47% | ― | ― | -13.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $40.89M | -1.08 | 248.50% | ― | ― | 36.06% | |
47 Neutral | $394.91M | -3.21 | -45.45% | ― | 2.33% | 36.86% | |
42 Neutral | $121.76M | -1.08 | -39.64% | ― | ― | -6.70% |
* Healthcare Sector Average
NKTX
Nkarta
1.70
-0.61
-26.41%
CGEN
Compugen
1.97
0.26
15.20%
CCCC
C4 Therapeutics
3.21
0.63
24.42%
STTK
Shattuck Labs
5.77
3.77
188.50%
TVGN
Tevogen Bio Holdings
6.28
-23.96
-79.23%
NVCT
Nuvectis Pharma
18.44
12.01
186.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.